All News
Tapering in RA?
In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
🧪 49% became MTX-free
⏱ 80% spaced OZR to q8w
CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8
LB0006 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Leaky pipeline in rheumatology:
In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men.
Top reasons?
🚫 Unfair promotion
🚫 Poor communication
🚫 No career path
Workplace equity still lags.
POS0407 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens.
⭐️🌱STAR/CRESS response rates also favoured active treatment.
Safe, accessible, affordable option for active disease.
@RheumNow #EULAR2025 #LB0005
Mrinalini Dey DrMiniDey ( View Tweet)
Nerandomilast: the new & improved nintedanib.
Does it work for our rheum pts?
Autoimmune subgroup of FIBRONEER-ILD (NEJM last month)
- mortality benefit vs placebo (this is new)
- well tolerated (minimal increase in diarrhoea vs placebo)
One to watch
#EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW
Links:
David Liew drdavidliew ( View Tweet)
FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast
1100+ pts, 320+ w/ SARD-ILD wk52
FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO
HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group
11% https://t.co/CeXWB2GlOe
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Guselkumab in APEX study (PsA, n=1020, biologic-naïve):
🦴 Less joint damage: 0.55 vs 1.35 (placebo)
💪 More responders: 67–68% hit ACR20 on GUS
🛡 Safety: similar to placebo
GUS - selective IL-23i - delivers joint protection and symptom relief
LB0010 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
Recommendations for RA management at #EULAR2025
- MTX [or other csDMARDs] and steroids still remain the first line- nothing beats that!
- ofcourse minimize steroids!
- rather than stopping meds at remission, reducing doses may be a better solution.
Not much changed.
@RheumNow https://t.co/NK5ejsgjWV
Bella Mehta bella_mehta ( View Tweet)
Proud to present the 1st #ARCH_ArLAR prospective interventional study #EULAR2025
Large awareness campaign ➡️
🔺️Proportion new referred CIRDs pts ⬆️ from 31 to 37%
🔺️Time 2 see a rheuma ⬇️ 14 to 10 mo
🔺️Time 2 diagnosis ⬇️ 18 to 12 mo
POS1310
@RheumNow
@ArLARheumatolog https://t.co/eKrRKHNXMZ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS.
Remission matters for subsequent Tx reduction.
@RheumNow #EULAR2025 #LB0006
Mrinalini Dey DrMiniDey ( View Tweet)
Suppression of inflammation fire 🔥 in #axSpA
may prevent subclinical atherosclerosis progression ❤️
🔺️90 patients
🔺️74% achieved LDA at 12 mo
🔺️Carotid plaque progression was higher in non-LDA group
POS1311
#EULAR2015
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Enpatoran (TLR7/8 inhibitor) in SLE & CLE
- helps skin, others?
- suppresses interferon
lowest dose was highest response though (upsetting primary endpoint)
Promising, watch for the ph3
No photos allowed, but official slides:
https://t.co/1yX6XrYvKH
#EULAR2025 LB0004 @RheumNow
David Liew drdavidliew ( View Tweet)
APEX study Ph3 RCT Guselkumab
In BioNaive active PsA w/ erosions>=2
wk 24
ACR20 GUS Q4W 67% Q8W 68% vs PBO 47%
Less Rx progression in both Q4W & Q8W vs. PBO
#EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ
Aurelie Najm AurelieRheumo ( View Tweet)
💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5).
@RheumNow #EULAR2025 #LB0007 #CART
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The relation between RA, comorbidities and presenteism
NRAS survey 891 RA pts
75% had at least one comorbidity
Absenteeism more likely if
One OR = 1.68 or Two OR = 2.26 comorbid conditions
In particular
Anxiety OR = 2.39
Depression OR = 1.75
Osteoarthritis OR = 1.85
Back
Aurelie Najm AurelieRheumo ( View Tweet)
The transformative potential of integrating ePROMs into AI care pathways
🔺️Study by Dr Antoni Chan et al. achieved a new-to-followup ratio of 1:2.5 outperforming the national average of 1:4.2
🔺️Without losing contact with pts
@synovialjoints
POS1271
#EULAR2025
@RheumNow https://t.co/z3jO3ADHR1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
